Aug. 2022 | Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility
Poxel Announces Extended Cash Runway with Debt Restructuring Agreement and Equity-linked Financing Facility Poxel SA, a clinical stage biopharmaceutical company developing innovative treatments for serious chronic diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, announced today that it has entered into (1) an agreement with IPF to restructure its existing debt…